Browse AFP

Summary
SymbolAFP
Namealpha-fetoprotein
Aliases HPAFP; AFPD; alpha-1-fetoprotein; alpha-fetoglobulin
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF00273 Serum albumin family
Function

Binds copper, nickel, and fatty acids as well as, and bilirubin less well than, serum albumin. Only a small percentage (less than 2%) of the human AFP shows estrogen-binding properties.

> Gene Ontology
 
Biological Process GO:0001542 ovulation from ovarian follicle
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007292 female gamete generation
GO:0007548 sex differentiation
GO:0008202 steroid metabolic process
GO:0008207 C21-steroid hormone metabolic process
GO:0008406 gonad development
GO:0008585 female gonad development
GO:0010817 regulation of hormone levels
GO:0022602 ovulation cycle process
GO:0030728 ovulation
GO:0034754 cellular hormone metabolic process
GO:0042180 cellular ketone metabolic process
GO:0042445 hormone metabolic process
GO:0042448 progesterone metabolic process
GO:0042698 ovulation cycle
GO:0045137 development of primary sexual characteristics
GO:0046545 development of primary female sexual characteristics
GO:0046660 female sex differentiation
GO:0048511 rhythmic process
GO:0048608 reproductive structure development
GO:0060395 SMAD protein signal transduction
GO:0061458 reproductive system development
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04390 Hippo signaling pathway
Reactome -
Summary
SymbolAFP
Namealpha-fetoprotein
Aliases HPAFP; AFPD; alpha-1-fetoprotein; alpha-fetoglobulin
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between AFP and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between AFP and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
27638840Germ Cell TumorInhibit immunity (infiltration)Expression of alpha-fetoprotein (AFP) RNA correlated with lack of the T-cell signature, with increasing AFP RNA inversely correlating with the inflamed signature and expression of IFNγ-associated genes.
20087354Hepatocellular CarcinomaPromote immunityAlpha-Fetoprotein (AFP) is a tumour-associated antigen in hepatocellular carcinoma (HCC) and is a target for immunotherapy.
24122861Hepatocellular CarcinomaPromote immunityImmunization with lentivector expressing optimized AFP, but not native AFP, completely protected mice from tumor challenge and reduced the incidence of carcinogen-induced autochthonous HCC. Epitope-optimization is required to break immune tolerance and potently activate AFP-specific CD8 T cells, generating effective antitumor effect to prevent clinically relevant carcinogen-induced autochthonous HCC in mice.
Summary
SymbolAFP
Namealpha-fetoprotein
Aliases HPAFP; AFPD; alpha-1-fetoprotein; alpha-fetoglobulin
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of AFP in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolAFP
Namealpha-fetoprotein
Aliases HPAFP; AFPD; alpha-1-fetoprotein; alpha-fetoglobulin
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of AFP in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.3040.211
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.1270.457
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.5440.351
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.390.678
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.1080.931
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0570.824
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of AFP in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.49.6-2.21
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.410.2-2.81
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolAFP
Namealpha-fetoprotein
Aliases HPAFP; AFPD; alpha-1-fetoprotein; alpha-fetoglobulin
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of AFP. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolAFP
Namealpha-fetoprotein
Aliases HPAFP; AFPD; alpha-1-fetoprotein; alpha-fetoglobulin
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of AFP. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by AFP.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolAFP
Namealpha-fetoprotein
Aliases HPAFP; AFPD; alpha-1-fetoprotein; alpha-fetoglobulin
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of AFP. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolAFP
Namealpha-fetoprotein
Aliases HPAFP; AFPD; alpha-1-fetoprotein; alpha-fetoglobulin
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of AFP expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolAFP
Namealpha-fetoprotein
Aliases HPAFP; AFPD; alpha-1-fetoprotein; alpha-fetoglobulin
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between AFP and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolAFP
Namealpha-fetoprotein
Aliases HPAFP; AFPD; alpha-1-fetoprotein; alpha-fetoglobulin
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting AFP collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.